BIOMAT Database Logo BIOMAT Database Logo

Insulinoma: a rare neuroendocrine pancreatic tumor. 2009

M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
4h Department of Surgery, University of Athens, School of Medicine, Attikon General Hospital, Athens, Greece. stamatakosmih@yahoo.gr

Insulinomas are functional endocrine tumors originating from the pancreatic b-cells. In 1902 Nicholls described the first adenoma of pancreatic islets, while the first insulinoma was described in 1927 in Mayo Clinic, which was dissected two years later in 1929 in Toronto. The first enucleation of insulinoma took place in a St. Jouis hospital in 1931, and after four years, in 1935, Whipple described the classic diagnostic triad: symptoms of fasting hypoglycemia or fatigue, blood glucose levels under 50 mg/dl and disappearance of symptoms after glucose administration.

UI MeSH Term Description Entries
D007003 Hypoglycemia A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. Fasting Hypoglycemia,Postabsorptive Hypoglycemia,Postprandial Hypoglycemia,Reactive Hypoglycemia,Hypoglycemia, Fasting,Hypoglycemia, Postabsorptive,Hypoglycemia, Postprandial,Hypoglycemia, Reactive
D007340 Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA. Adenoma, beta-Cell,Insuloma,beta-Cell Tumor,Adenoma, beta Cell,Adenomas, beta-Cell,Insulinomas,Insulomas,Tumor, beta-Cell,Tumors, beta-Cell,beta Cell Tumor,beta-Cell Adenoma,beta-Cell Adenomas,beta-Cell Tumors
D010180 Pancreatectomy Surgical removal of the pancreas. (Dorland, 28th ed) Pancreatectomies
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012383 Romania A country in southeastern Europe, bordering the Black Sea, between Bulgaria and Ukraine. The capital is Bucharest. Rumania,Roumania
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D049673 History, 20th Century Time period from 1901 through 2000 of the common era. 20th Century History,20th Cent. History (Medicine),20th Cent. History of Medicine,20th Cent. Medicine,Historical Events, 20th Century,History of Medicine, 20th Cent.,History, Twentieth Century,Medical History, 20th Cent.,Medicine, 20th Cent.,20th Cent. Histories (Medicine),20th Century Histories,Cent. Histories, 20th (Medicine),Cent. History, 20th (Medicine),Century Histories, 20th,Century Histories, Twentieth,Century History, 20th,Century History, Twentieth,Histories, 20th Cent. (Medicine),Histories, 20th Century,Histories, Twentieth Century,History, 20th Cent. (Medicine),Twentieth Century Histories,Twentieth Century History

Related Publications

M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Insulinoma, a rare neuroendocrine tumor: a case report.
January 2005, Hawaii medical journal,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Transformation of pancreatic nonfunctioning neuroendocrine tumor into metastatic insulinoma: A rare case report.
November 2023, Clinical case reports,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Malignant Insulinoma: A Rare Form of Neuroendocrine Tumor.
July 2020, World journal of surgery,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Malignant Insulinoma Arising From Nonfunctioning Pancreatic Neuroendocrine Tumor.
January 2023, ACG case reports journal,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Pancreatic Insulinoma: Case Report of Rare Tumor.
December 2019, Cureus,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Diffuse Pancreatic Neuroendocrine Tumor: A Rare Presentation.
January 2018, Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Relevant infrastructural alterations in a pancreatic neuroendocrine tumor: an insulinoma case.
January 2014, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Transition of a pancreatic neuroendocrine tumor from ghrelinoma to insulinoma: a case report.
April 2015, Journal of gastrointestinal oncology,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Pancreatic neuroendocrine tumors with transformation to insulinoma: an unusual presentation of a rare disease.
January 2015, Endocrinology, diabetes & metabolism case reports,
M Stamatakos, and C Safioleas, and S Tsaknaki, and P Safioleas, and R Iannescu, and M Safioleas
Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.
March 2018, Medical molecular morphology,
Copied contents to your clipboard!